Novelis says it will sell two China subsidiaries for $265 million, moves described across outlets as a step back from its China operations. The transaction is presented as a corporate restructuring decision rather than an immediate production shutdown.
The Economic Times frames the development as the company taking a $265 million step back from China, emphasizing the geographic shift. Investing.com similarly focuses on the sale of two specific subsidiaries for the same amount, highlighting the asset-disposal nature of the move. Based on the available summaries, both outlets align on the core facts: Novelis is selling two China entities and the deal value is $265 million.
